Integromat Evolves to Make, Expanding Its Vision to Empower Creators to Innovate Without Limits
Today, no-code integration platform Integromat, launched “Make”. Make represents the name of the brand, business, and the new product—a visually intuitive platform that lets you design, build, and automate anything from simple workflows to complex processes, without coding. The new brand name and identity has evolved alongside the new product to capture the broader vision for a world where everyone has the power to innovate without limits.
“Make captures the evolution of our platform, the spirit of our customers, and reflects one of the most transformational trends of our era: from rigid, top-down, repetitive jobs to flexible, empowering, and meaningful work. Our users aren’t just connecting apps or automating workflows; they are creatively responding to workplace challenges by building solutions,” said Ondřej Gazda, CEO of Make. “Put simply, we’ve realized our users aren’t just users, they’re Makers.”
Make is paving a new future for no-code and redefining what it means to be a visual platform. No-code tools are often represented by the typical visual drag-and-drop feature; for Make, visual means something different. Make allows teams to visualize, modify, and collaborate on processes that scale as quickly as their organization. Make offers an intuitive and playful experience, which sets it further apart from other automation tools.
“No-code tools are just that; they enable users to build and automate without writing any code. Make offers much more: a visual language that democratizes development, makes processes tangible and fosters team collaboration, regardless of technical skills,” said Patrik Simek, CTO of Make. “It’s also fun and exciting to create on Make. Once you realize what’s possible—it feels like there are no limits. Empowering humans to innovate doesn’t just change the future of how we work—it also changes the world.”
Small businesses, startups, scale-ups, teams and enterprises all around the world can now create powerful solutions #withMake to scale their businesses faster than ever.
The Make platform is based upon a new architectural foundation that provides dramatically increased scalability and performance. It also includes new, lol highly requested capabilities with the familiar visual experience Integromat customers love. Users can also benefit from the ability to run their critical processes hosted in a region of their choice, Europe or North America (with more regions to come).
Integromat was acquired by Celonis in 2020. Now, one and a half years later, Make is launched as its own business unit within Celonis. Integromat will remain as a legacy product offering through 2022. All existing customers will have the opportunity to seamlessly upgrade to Make over the course of next year. New customers can register for Make and begin to take advantage of the new platform immediately.
About Make
Make is the leading visual platform for anyone to design, build, and automate anything—from tasks and workflows to apps and systems—without the need for coding skills. Make enables individuals, teams, and enterprises across all verticals to create powerful custom solutions that scale their businesses faster than ever. Make powers over 500,000+ organizations around the globe. Learn more about Make at www.make.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005231/en/
Contact information
Shiran Brodie
Head of Marketing
press@make.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility23.10.2025 16:03:00 EEST | Press release
SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facility to expand and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification. This expansion, combined with SK pharmteco’s industry-leading chromatography expertise and existing development and manufacturing capabilities in the United States, positions the company to meet the rising demand for U.S. peptide development and domestic clinical and commercial manufacturing. "The investment in our California facility represents a key milestone in our strategic growth and demonstrates an unwavering dedication to the domestic biopharma sector,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Peptides are a vital and rapidly advancing therapeutic category. This project highlights our ongoing commitment to furthering their development and manufacturing.” “We are expanding our capacity to meet the increasing
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK ® at the North American Cystic Fibrosis Conference23.10.2025 16:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington. Several of the abstracts that will be presented at this year’s conference demonstrate that improvement in CFTR function, as measured by reduction in sweat chloride (SwCl), is associated with improved outcomes in people with cystic fibrosis (CF). ALYFTREK has shown greater reductions in sweat chloride compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Phase 3 trials, suggesting that ALYFTREK has the potential for even greater improvements in quality of life and other health-related outcomes. Data being presented on ALYFTREK and on correlation between lower SwCl and improved clinical
Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 202523.10.2025 16:00:00 EEST | Press release
Boomi™, the leader in AI-driven automation, today announced it has been named an Exemplary Vendor in both the ISG Buyers Guide™ for Data Integration and the ISG Buyers Guide™ for Master Data Management 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023515342/en/ Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 2025 In these independently published reports from ISG Software Research, a division of ISG (Information Services Group), Boomi was recognized as a Leader across multiple evaluation dimensions, including Product Experience, Capability, Customer Experience, and Validation. Customer Experience and Validation The ISG Buyers Guide™ assessments are widely used by enterprise technology buyers to evaluate market-leading software solutions. Boomi’s placement in both guides reflects its commitment to delivering a unified, AI-ready platform that helps orga
CWAN and J.P. Morgan Asset Management Launch Automated Cash Management Solution for Hedge Funds23.10.2025 16:00:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, and J.P. Morgan Asset Management today announced an integration that transforms how hedge funds manage cash. The solution links Enfusion by CWAN directly with the Morgan Money® trading platform, J.P. Morgan Asset Management’s short-term investment management solution, giving clients a single, automated workflow for investing and monitoring idle cash. Through this connection, hedge funds can now: Maximize idle cash by automatically investing in a diversified range of money market funds. Reduce concentration risk by spreading cash across multiple managers, custodians, and currencies. Improve liquidity visibility through real-time data and automated withdrawal and deposit capabilities. Eliminate manual treasury work, freeing teams to focus on trading and strategy. “Every dollar sitting in a single account represents both a missed opportunity and unnecessary concentration risk,” said Sc
Foresight Launches the First Conversational AI Interface to Query Unified Private Market Data23.10.2025 15:07:00 EEST | Press release
Foresight is ushering in the next generation of private market software by letting its customers use natural language to query their unified pre- and post-deal data. Today, the company announced new AI capabilities that will give customers the ability to ask questions within the Foresight platform as well as in ChatGPT, Claude, and Glean through its new model context protocol (MCP) server. Private market dealmakers will be able to prompt Foresight’s AI for lists of prospective companies, and anyone who makes post-deal decisions will be able to ask portfolio questions, model scenarios, and execute workflows in natural language on Foresight’s desktop or mobile interfaces. “The $15 trillion private market has run on data silos and Excel, which has created unnecessary opacity. Foresight unlocks the data and analytics that fund managers and financial institutions need by using AI to unify the systems and sources of private market data and making it actionable through great user interfaces f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom